Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Cash & Equivalents (2016 - 2025)

Pediatrix Medical (MD) has disclosed Cash & Equivalents for 17 consecutive years, with $375.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 63.19% to $375.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $375.2 million, a 63.19% increase, with the full-year FY2025 number at $375.2 million, up 63.19% from a year prior.
  • Cash & Equivalents was $375.2 million for Q4 2025 at Pediatrix Medical, up from $340.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $387.4 million in Q4 2021 to a low of $5.8 million in Q2 2023.
  • A 5-year average of $145.0 million and a median of $86.1 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: tumbled 97.58% in 2022, then surged 1137.53% in 2025.
  • Pediatrix Medical's Cash & Equivalents stood at $387.4 million in 2021, then plummeted by 97.46% to $9.8 million in 2022, then surged by 645.7% to $73.3 million in 2023, then soared by 213.88% to $229.9 million in 2024, then skyrocketed by 63.19% to $375.2 million in 2025.
  • Per Business Quant, the three most recent readings for MD's Cash & Equivalents are $375.2 million (Q4 2025), $340.1 million (Q3 2025), and $224.7 million (Q2 2025).